Mounjaro vs Zepbound
Same Tirzepatide — Different FDA Indication, Different Insurance Coverage
Mounjaro and Zepbound are the same drug: tirzepatide, Eli Lilly's dual GIP+GLP-1 receptor agonist. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Dosing is identical (2.5–15 mg weekly), side effects are identical — only the label, indication, and insurance coverage differ. Track either in Shotlee.
Mounjaro vs Zepbound at a Glance
Mounjaro (Tirzepatide for T2D)
- →FDA indication: type 2 diabetes management
- →Dose range: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly
- →Maximum approved dose: 15 mg weekly
- →Key T2D trials: SURPASS programme (−2.3% HbA1c at 15 mg)
- →SURMOUNT data also shows ~22% weight loss at 15 mg
- →Often used off-label for weight loss by prescriber discretion
- →Insurance: generally covered for T2D indication
Zepbound (Tirzepatide for Obesity)
- →FDA indication: chronic weight management (November 2023)
- →Also approved for obstructive sleep apnea (2024) — first drug for this
- →Dose range: identical to Mounjaro (2.5–15 mg weekly)
- →Key obesity trial: SURMOUNT-1 (~20.9% weight loss at 15 mg)
- →SURMOUNT-5 (2025): ~47% more weight loss than Wegovy
- →Eli Lilly offers lower-cost single-dose vials for self-pay patients
- →Insurance: covered by obesity benefit plans; excluded from many standard plans
Head-to-Head Comparison
| Factor | Mounjaro | Zepbound |
|---|---|---|
| Active molecule | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Obesity + obstructive sleep apnea |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Dose escalation | Same 4-week steps | Same 4-week steps |
| Weight loss data | ~22% at 15 mg (SURMOUNT-4 T2D) | ~20.9% at 15 mg (SURMOUNT-1 obesity) |
| Sleep apnea approval | No | Yes (2024) |
| T2D insurance coverage | Usually covered | Usually not covered |
| Obesity insurance coverage | Off-label only | Covered if qualifying |
| Monthly cost (uninsured) | ~$1,000–1,200 | ~$1,000–1,200 (autoinjector); lower via Lilly vials |
SURMOUNT-1 (Jastreboff et al., NEJM 2022) for obesity data; SURPASS trials for T2D data. [1, 2]
Key Numbers
Zepbound 15 mg (SURMOUNT-1)
20.9%
Mean body weight loss at 72 weeks in SURMOUNT-1 (N=2539, adults with obesity, no T2D).
Mounjaro HbA1c (SURPASS-2)
−2.3%
Mean HbA1c reduction at 40 weeks with tirzepatide 15 mg in the SURPASS-2 T2D trial.
SURMOUNT-5 vs Wegovy
~47%
More relative weight loss with tirzepatide vs semaglutide in the 2025 SURMOUNT-5 direct head-to-head.
Choose Based on Your Goal
You have type 2 diabetes
Weight loss is the primary goal
Obstructive sleep apnea
Insurance covers T2D but not obesity
Cost for self-pay patients
Why Two Brand Names?
Pharmaceutical companies seek separate FDA approvals for different indications — even when the drug is identical. This allows them to market the product to different specialties (endocrinology vs obesity medicine), negotiate insurance coverage separately, and set different formulary positions. The pharmacology is completely unchanged.
Zepbound gained an additional approval in 2024 for obstructive sleep apnea — the first medication ever specifically approved for this condition — making it the more versatile option for patients with multiple weight-related conditions.
If you have type 2 diabetes, your doctor will typically prescribe Mounjaro for better insurance coverage. If your primary goal is weight loss or you have sleep apnea, Zepbound is the on-label choice. In practice, the drugs are interchangeable — the brand name determines coverage.
Track Either in Shotlee
Shotlee supports both Mounjaro and Zepbound with the full 2.5–15 mg dose escalation schedule, injection reminders, weight tracking, and side effect logs. Switching brands does not affect your history.
Mounjaro vs Zepbound: Common Questions
Yes — both contain tirzepatide at identical doses. The distinction is purely in FDA indication and brand positioning. If you switched from Mounjaro to Zepbound, you are taking the exact same drug.
Both reach the same maximum of 15 mg weekly, with the same dose escalation schedule (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). There is no pharmacological difference between the two products.
Yes, doctors can prescribe Mounjaro off-label for weight loss, but insurance typically will not cover it without a diabetes diagnosis. Zepbound is the FDA-approved on-label option for weight management.
Yes. In 2024, Zepbound became the first medication ever approved specifically for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro does not have this indication.
Eli Lilly launched Zepbound single-dose vials at lower prices to compete with compounded tirzepatide. Autoinjector pens for both brands are similarly priced, but Lilly's self-pay vial programme offers Zepbound at a lower cost for uninsured patients.
References
Track Mounjaro or Zepbound in Shotlee
Full 2.5–15 mg dose escalation tracking, injection reminders, and weight charts. Free.
🚀 Use Shotlee for Free